natgillin/translations-raw huggingface dataset:
The application according to claim 3, characterized in that the inflammation mainly comprises one of rheumatoid arthritis, gouty arthritis, osteoarthritis and rachitis, further comprises one of systemic lupus erythematosus, psoriasis, eczema, skin inflammation and postpartum inflammation, bowel disease, gastritis, irritable bowel syndrome, headache, exarteritis, thyroiditis, aplastic anemia, retinitis, conjunctivitis, retinopathy, uveitis, hemeralopia, acute ocular tissue injury, viral infection and cystic fibrosis, allergic rhinitis, postpartum pain, toothache, muscle pain, cancer pain, aneurysm, coronary plaque inflammation, inflammation caused by bacteria, inflammation caused by viruses, inflammation caused by surgery, ocular vascular hyperplasia, retinal vascular hyperplasia and gastric ulcer. 
Deuterirani benzopiranski spoj ili farmaceutski prihvatljiva sol prema bilo kojem od prethodno navedenih patentnih zahtjeva za upotrebu u liječenju inflamacije naznačene reumatoidnim artritisom, gihtom, osteoartritisom i rahitisom, ili podrazumjeva jedan sistemski eritemski lupus, psorijazu, ekcem, inflamaciju kože i postpartalnu inflamaciju, bolesti crijeva, gastritis, sindrom iritabilnog crijeva, glavobolju, periarteritis, tiroiditis, aplastičnu anemiju, retinitis, konjuktivitis, retinopatije, uveitis, hemeralopiju, akutnu očnu povredu tkiva, virusne infekcije i cistične fibroze, alergijski rinitis, postpartalni bol, zubobolju, mišićinu bol, bol uslijed kancerogenog oboljenja, aneurizmu, koronarnu plak inflamaciju, inflamaciju uzrokovanu bakterijama, inflamaciju uzrokovanu virusima, inflamaciju uzrokovanu kirurški, okularnu vaskularnu hiperplaziju, retinalnu vaskularnu hiperplaziju i peptički ulkus.
Simplified Irwin test 
Pojednostavljen Irwin test
The antibody of claim 6, wherein the heavy chain comprises amino acid residues 20 to 466 of SEQ ID NO: 31 and the light chain comprises amino acid residues 20 to 237 of SEQ ID NO: 36. 
Antitijelo prema patentnom zahtjevu 6, naznačeno time što teški lanac sadrži aminokiselinske ostatke 20 do 466 iz sekv. id. br.: 31 i lagani lanac sadrži aminokiselinske ostatke 20 do 237 iz sekv. id. br.: 36.
In tablets, the active component is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted to the desire shape and size. 
Kod tableta, aktivni sastojak je pomiješan sa podlogom koja ima neophodan kapacitet vezivanja u prikladnim proporcijama i zatim tiskan u željeni oblik i veličinu.
Psychosis is often considered to be a symptom of severe mental illness. 
Psihoza se često smatra simptomom ozbiljne mentalne bolesti.
An audio signal decoding method for decoding an encoded audio signal including a plurality of frames, using a first decoding means operating under a linear predictive coding scheme and a second decoding means operating under a coding scheme which is different from the linear predictive coding scheme, the audio signal decoding method comprising: 
Postupak dekodiranja audio signala, namijenjen dekodiranju kodiranog audio signala koji sadrži više okvira, uz pomoć prvog dekodera (24), koji radi prema linearnoj prediktivnoj shemi kodiranja, i drugog dekodera (25), koji radi prema shemi kodiranja koja se razlikuje od linearne prediktivne sheme kodiranja, naznačen time što se postupak dekodiranja audio signala sastoji u:
A pharmaceutical composition comprising a compound having the formula 
Spoj s formulom (I) [image] naznačen time da
[Paragraph 10] Use of a compound of Formula I as defined in paragraph 1 or a pharmaceutically acceptable salt thereof as a GSNOR inhibitor. 
Uporaba spoja formule I prema zahtjevu 1 ili zahtjevu 6, naznačena time, da služi kao GSNOR-inhibitor in vitro.
A compound of claim 1 or 7, wherein m is 0-2, optionally 0-1. 
Spoj u skladu s patentnim zahtjevom 1 ili 7, naznačen time, da je m 0 do 2, po izboru od 0 do 1.
A diagnosis of insulin resistance can also be made using the euglycemic glucose clamp test. 
Dijagnoza inzulinske rezistencije se također može provesti uporabom euglikemijskog testa gomilanja glukoze.
Device for using a capsule (1, 1') according to any one of claims 1 to 10, characterized in that it comprises at least one extraction chamber (10) to carry out the process according to any of claims 11 to 14. 
Uređaj za korištenje kapsule (1, 1') u skladu s bilo kojim od patentnih zahtjeva 1 do 10, naznačen time, da sadrži najmanje jednu komoru za ekstrakciju (10) za provođenje postupka prema bilo kojem od patentnih zahtjeva 11 do
A compound of any one of claim 1 to 11 or a pharmaceutically acceptable salt thereof for use in the treatment, prevention or management of diseases or disorders, syndromes or conditions associated with the modulation of calcium release-activated calcium (CRAC) channel. 
Uporaba spoja prema bilo kojem od patentnih zahtjeva 1 do 4 ili njegove farmaceutski prihvatljive soli za pripremu lijeka za liječenje, prevenciju ili upravljanje bolesću 1li poremećaja, sindroma ili stanja povezanih sa modulacijom kalcijeva kanala aktiviranog oslobađanjem kalcija (CRAC).
a group of tobacco articles; 
skupinu duhanskih proizvoda;
Packaging article according to claim 5 or 6, characterized in that the materials providing the barrier means (1) are chosen from a group consisting of silicium oxide (SiOx), a coating of PVDc, a special nylon such as MXD6 mixed into the basis material or EVOH (ethyl-vinyl-alcohol). 
Ambalažni proizvod prema zahtjevu 5 ili 6, naznačen time da su materijali za pregradna sredstva (1) odabrani iz skupine koja sadrži silicijev oksid (SiOx), PVDc prevlaku, posebni najlon kao što je MXD6 pomiješan u osnovni materijal ili EVOH (etil-vinil-alkohol).
is a heteroaryl ring represented by the formula 
R' je heteroarilni prsten predstavljen formulom DID? o
A compound or pharmaceutically acceptable salt thereof selected from the group consisting of: 1-((6-(trans-4-tert-butylcyclohexyloxy)quinazolin-2-yl)methyl)piperidine-4-carboxylic acid; 
Spoj odabran iz skupine koju čine: -((6-(trans-4-tert-butilcikloheksiloksi)kinazolin-2-il)metil)piperidin-4-karboksilna kiselina;
A maintenance period wherein Cladribine pharmaceutical formulation is administered and wherein the total dose of Cladribine reached at the end of the maintenance period is lower than the total dose of Cladribine reached at the end of the induction period (i); 
period održavanja, koji traje od 2 mjeseca do 4 mjeseca, kada navedenu kladribinsku farmaceutsku formulaciju treba primjenjivati i kada je ukupna doza kladribina postignuta na kraju perioda održavanja manja od ukupne doze kladribina postignute na kraju perioda uvođenja (i);
A compound of the formula: or 
Spoj s formulom: [image] [image] [image] ili [image]
Method and device of detecting the operational mode of a beverage system 
METODA I UREĐAJ ZA DETEKTIRANJE OPERATIVNOG NAČINA RADA SISTEMA ZA NAPITKE
Electric heating system, a control head and a heating liquid 
ELEKTRIČNI SUSTAV GRIJANJA, KONTROLNA GLAVA I TEKUĆINA ZA ZAGRIJAVANJE
The proteinaceous construct of claim 1 wherein said molecule retains at least 50% of native FVIII activity, preferably at least 80% of native FVIII activity. 
Postupak prema zahtjevu 1, pri čemu navedeni FVIII konjugiran sa polimerom topivim u vodi zadržava barem 80% prirodne biološke aktivnosti FVIII.
Non-phytotoxic oils and oil concentrates can also be added. 
Ne-fitotoksična ulja i koncentrati ulja se također mogu dodati.
In other embodiments of the invention, the melt extruded material is prepared without the inclusion of the opioid agonist and/or opioid antagonist, which are added thereafter to the extrudate. 
Farmaceutski proizvod prema bilo kojem od prethodnih zahtjeva, naznačen time da je sloj supstancijalno lišen antagonista ifili je oblik za doziranje lišen izravnog oslobađanja antagonista i/ili čestice opioidnog antagonista imaju prosječni promjer od oko 0.1 do oko 6.0 mm.
measuring oxygen content of the regeneration gas (RG) to be fed into the filter (5) and/or that has passed through the filter (5); and 
mjerenja sadržaja kisika regeneracijskog plina (RG), koji treba dovesti u filter (5) i/ili koji je prošao kroz filter (5); 1
The surgical cassette of claim 1, wherein the sheet (107) is an elastomeric sheet. 
Kirurška kazeta prema zahtjevu 1, naznačena time, da je pločica (107) jedna elastomerna pločica.
A composition for use according to claim 1 for increasing an initial period of undisturbed sleep and/or reducing nocturnal voids in a female patient above 50 years of age. 
Pripravak za uporabu prema zahtjevu 1 naznačen time da je za liječenje pacijentice starije od 65 godina.
Any of the above embodiments are also embodiments of formula IF with the proviso that R11 does not exist in compounds of general formula IF. 
Bilo koji od oblika koji su gore navedeni također predstavljaju oblike formule IF pod uvjetom da R'' ne postoji u spojevima opće formule IF.
The anti-FOLR1 antibody or anti-FOLR1 immunoconjugate for use of claim 1, wherein the detection method comprises detecting FOLR1 expression with the antibody BN3.2 
Protutijelo protiv FOLR1 ili imunokonjugat protiv FOLR1, namijenjeni upotrebi u skladu s patentnim zahtjevom 1, naznačeni time što se postupak detektiranja sastoji u detektiranje eksprimiranja FOLR1 protutijelom BN3.2.
the surveillance tool thus determines the times with the engine running with the machine stopped and the times with the engine running with the machine in motion. 
- te kontrolni uređaj (2) tako određuje vrijeme kada je motor upaljen sa zaustavljenim uređajem i vrijeme kada je motor upaljen sa uređajem u kretanju.
The product of the reaction of the lithiated compound XXI and the electrophile VIII can be activated as a sulfonyl ester after transformation of J into a hydroxyl group by methods known to the persons skilled in the art and detailed in the textbook Protective Groups in Organic Synthesis, Greene and Wuts, Wiley Interscience, (1991), ISBN 0471623016. 
Proizvod reakcije liliranog spoja XXI 1 elektrolita VIII može se aktivirati kao sulfonil ester nakon transformacije J u hidroksilnu grupu na načine poznate struci i opisane u udžbeniku Protective Groups in Organic Synthesis, Greene i Wuts, Wiley Interscience, (1991.), ISBN 0471623016.
The aqueous solution according to anyone of claims 1 to 3, further comprising at least one non-aromatic preservative agent, at least one flavouring agent, a buffer and/or at least one viscosity increasing agent. 
Vodena otopina sukladno bilo kojem od zahtjeva 1 do 2, naznačeno time, da nadalje sadrži najmanje jedno sredstvo za poboljšanje okusa i/ili najmanje jedno sredstvo za povećanje viskoznosti.
A solution of 5-bromomethyl-1-methyl-1H-benzotriazole (0.044 g, 0.196 mmol) in DMF (1 ml) is added to the cooled solution and the resulting mixture is agitated at room temperature for 2 days. 
U ohlađenu otopinu doda se otopinu 5-brom-metil-1- metil-1H-benzotriazola (0,044 g, 0,196 mmola) u DMF-u (1 ml) i dobivenu smjesu se miješa 2 dana pri sobnoj temperaturi.
(xiii) phenyl optionally substituted with Cl; 
(xtii) fenil po izboru supstituiran s Cl;
Note that in the following the invention will be explained referring to a certain design of a capsule, i.e. a design according to which the capsule comprises a cup-like base body and a closing foil member. 
Napominje se da će, u tekstu koji slijedi, ovaj izum biti objašnjen s obzirom na određenu izvedbu čahure, to jest izvedbu u skladu s kojom čahura ima tijelo baze u obliku čašice i foliju kao element za zatvaranje.
The compound of claim 11, wherein the cardiac disorders and diseases are selected from the group consisting of irregular heartbeat disorders and diseases; exercise-induced irregular heartbeat disorders and diseases; sudden cardiac death; exercise-induced sudden cardiac death; congestive heart failure; chronic obstructive pulmonary disease; and high blood pressure. 
Spoj prema patentnom zahtjevu 11, naznačen time što su poremećaji i bolesti srca izabrani iz grupe koju čine poremećaji i bolesti nepravilnog srčanog rada; poremećaji i bolesti nepravilnog srčanog rada inducirani pojačanom fizičkom aktivnošću; iznenadna srčana smrt; iznenadna srčana smrt inducirana pojačanom fizičkom aktivnošću; kongestivna srčana insuficijencija; kronična opstruktivna bolest pluća; i visok krvni tlak.
optionally in RIFLE stage 0, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage R, I or F within 72 hours, within 48 hours or within 24 hours, wherein the subject is optionally in RIFLE stage 0, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage I or F within 72 hours, within 48 hours or within 24 hours or wherein the subject is optionally in RIFLE stage 0, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 72 hours, within 48 hours or within 24 hours or 
može biti u RIFLE stadiju 0, a navedeni korak koreliranja obuhvaća pridruživanje vjerojatnosti da subjekt dospije u RIFLE stadij R, I ili F unutar 72 sata, unutar 48 sati ili unutar 24 sata, gdje subjekt može biti u RIFLE stadiju 0, a navedeni korak koreliranja obuhvaća pridruživanje vjerojatnosti da subjekt dospije u RIFLE stadij I ili F unutar 72 sata, unutar 48 sati ili unutar 24 sata ili gdje subjekt može biti u RIFLE stadiju 0, a navedeni korak koreliranja obuhvaća pridruživanje vjerojatnosti da subjekt dospije u RIFLE stadij F unutar 72 sata, unutar 48 sati ili unutar 24 sata ili
After stirring at room temperature for a further 2 hours, the reaction mixture is partitioned between ethyl acetate/ether (300 ml of a 1:1 mixture) and water (30 ml). 
Nakon miješanja pri sobnoj temperaturi daljnja 2 sata, reakcijsku smjesu se podijeli između etil acetata i etera (300 ml 1:1 mješavine) i vode (30 ml).
a vector according to claim 6, and 
(i) vektor prema zahtjevu 6, i
The anti-CD79b antibody of claim 21, wherein the substitution mutation is selected from the group consisting of N297G, N297A, L234A, L235A, and D265A according to EU numbering. 
Anti-CD79b protutijelo patentnog zahtjeva 11, naznačeno time, da je zamjenska mutacija odabrana iz skupine koja se sastoji iz N297G, N297A, L234A, L235A i D265A prema EU numeriranju.
The composition of claim 1, wherein the dehydration treatment is carried out after the anti-mold treatment, and before putting the olives into a bottle. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time da se obrada dehidracije provodi nakon tretiranja protiv plijesni, a prije stavljanja maslina u bocu.
The conjugate according to either claim 1 or claim 2 wherein the antibody comprises: a VL domain comprising a VL CDR1 with the amino acid sequence of SEQ ID NO.6, a VL CDR2 with the amino acid sequence of SEQ ID NO.7, and a VL CDR3 with the amino acid sequence of SEQ ID NO.8. 
Konjugat prema zahtjevu 1 ili zahtjevu 2, naznačen time, da protutijelo obuhvaća sljedeće: VL-domenu koja sadrži VL CDR1 s aminokiselinskom sekvencom od SEQ ID NO. 6, VL CDR2 s aminokiselinskom sekvencom od SEQ ID NO. 7, i VL CDR3 s aminokiselinskom sekvencom od SEQ ID NO. 8.
Manoeuvrable dredging vessel according to a preceding claim, wherein the respective clutch devices of the trailing transmission shaft and the sailing transmission shaft are arranged outside the shaft housing. 
Upravljivo ploveće jaružalo u skladu s prethodnim patentnim zahtjevom, naznačeno time što se odgovarajuće spojke stražnjeg transmisijskog vratila i prednjeg transmisijskog vratila nalaze izvan kućišta vratila.
The DII4 antagonist for use according to claim 3, wherein the antibody or fragment thereof comprises (a) a HCVR sequence of SEQ ID NO:20 or 116 and a LCVR sequence of SEQ ID NO:28 or 118, or (b) a HCVR/LCVR combination of SEQ ID NO:20/28 or 116/118. 
Antagonist DIlI4 za primjenu prema zahtjevu 3, naznačen time, što se antitijelo ili njegov fragment sastoji od (a) HCVR sekvence od SEQ ID NO: 20 ili 116 i LCVR sekvence od SEQ ID NO:28 ili 118, ili (b) kombinacije HCVR/LCVR od SEQ ID NO: 20/28 ili 116/118.
The main frame 26 is composed of a left frame 1, a right frame 2, a lever axis 3, a upper frame 4, a rear frame 5 and a lower frame 6. 
Glavni okvir 26 je sastavljen od lijevog okvira 1, od desnog okvira 2, osovinc poluge 3, gornjeg okvira 4, stražnjeg okvira 5 i donjeg okvira 6.
Thereby the capsule (24) is actively detached from the both jaw members when the extraction module is transferred from its closed state to its opened state. 
Pri tome se čahura aktivno odvaja od oba elementa čeljusti nakon što modul za ekstrakciju pređe iz zatvorenog položaja u otvoreni položaj.
The pharmaceutical composition of claim 10, wherein said OPACs express one or more of the proteins decorin, epiregulin, IGFBP-3, IGFBP-6, IL-2 R alpha, IL-17RC, IL-27, Latent TGF-beta binding protein 1 (LTBP), NCAM-1, Smad4, TFPI, TGF-beta R1/ALK5 or TIMP-2. The pharmaceutical composition of claim 10, wherein said OPACs express the proteins decorin, epiregulin, IGFBP-3, IGFBP-6, IL-2 R alpha, IL-17RC, IL-27, Latent TGF-beta binding protein 1 (LTBP), NCAM-1, Smad4, TFPI, TGF-beta R1/ALK5 and TIMP-2. 
Izolirana populacija stanica u skladu s patentnim zahtjevom 15, naznačena time što stanice u navedenoj populaciji stanica eksprimiraju jedan ili više proteina dekorin, epiregulin, IGFBP-3, IGFBP-6, IL-2 R alfa, IL-17RC, IL-27, latentni TGF-beta-vežući protein 1 (LTBP), NCAM-1, Smad4, TFPI, TGF-beta RI/ALKS ili TIMP-2, ili gdje stanice u navedenoj populaciji stanica eksprimiraju proteine dekorin, epiregulin, IGFBP-3, IGFBP-6, IL-2 R alfa, IL-17RC, IL-27, latentni TGF-beta-vežući protein 1 (LTBP), NCAM-I, Smad4, TFPI, TGF-beta RI/ALKS 1 TIMP-2.
is selected from the group consisting of hydrogen, alkyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heteroarylalkyl, and (NRCRD)sulfonyl; and RC and RD are independently selected from the group consisting of hydrogen and alkyl. 
Rg je odabran iz skupine koja se sastoji od vodika, alkila, arilalkila, cikloalkila, cikloalkilalkila, heterocikla, heteroarilalkila i (NRcRp)sulfonila; i
a fermentation step for the production of the biologically active compound, 
- korak fermentacije za proizvodnju biološki aktivnog spoja
For treatment, invention peptide sequences can be administered to subjects having a fasting plasma glucose (FPG) level greater than about 100 mg/dl. 
(i) ima razinu glukoze u plazmi natašte (FPG) veću od 100 mg / dl; (ii) daje razina FPG veća od 125 mg / dl;
Soft-tissue rheumatism Allergies or pseudoallergic diseases, which coincide with inflammatory and/or proliferative processes: 
(iii) alergija ili pseudo alergijskih bolesti, koje se poklapaju s upalnim i/ili proliferativnim procesima,
Next, one switches the receiver on, using a fixed switch installed at or near the receiver. 
Nadalje, uključuje se prijemnik, korištenjem fiksne sklopke postavljene na ili u blizini prijemnika.
In some embodiments, the disease can include Alzheimer's disease, bovine spongiform encephalopathy (BSE), Parkinson's disease, Huntington's disease, Down's Syndrome, Dementia with Lewy Body, or Amyotrophic Lateral Sclerosis (ALS). In some embodiments, the amyloid peptide is AB peptide and the disease is Alzheimer's disease. 
Spoj ili pripravak prema bilo kojem od patentnih zahtjeva 1 do 9 naznačen time da je za uporabu prema zahtjevu 10, pri čemu je bolest Alzheimerova bolest, goveđa spongiformna encefalopatija (GSE), Parkinsonova bolest, Huntingtonova bolest, Downov sindrom, demencija s Lewyjevim tjelešcima, ili amiotrofična lateralna skleroza (ALS).
The method according to claim 1, wherein the disease or disorder is lung cancer. 
Spoj za uporabu prema zahtjevu 1, naznačen time, da bolest ili poremećaj je genitalno-urinarni Tak.
reclosing the at least one seal. 
ponovno zatvaranje najmanje jednog zatvarača.
UV light at a wavelength of 200 nm to 300 nm, more preferably at a wavelength of 220 nm to 254 nm. 
(1i) UV svjetlost kod valne duljine od 200 nm do 300 nm, poželjnije kod valne duljine od 220 nm do 254 nm.
a retrovirus selected among reticulo-endotheliosis virus, duck infectious anemia virus, suck spleen necrosis virus, or a recombinant retrovirus thereof; 
retrovirus izabran između virusa retikulo-endotelioze, virus pačje zarazne anemije, virus nekroze pačje slezene, ili njihov rekombinantni retrovirus;
The method of claim 1, wherein the pharmaceutical composition is in a hermetically sealed container selected from the group consisting of a vial, a sachette, a pre-filled syringe, a pre-filled autoinjector, a cartridge for a reusable syringe, and an applicator. 
Farmaceutski pripravak za uporabu u skladu s jednim od patentnih zahtjeva 1 do 11, naznačen time da oblik jediničnog doziranja sadrži protutijelo ili njegov fragment koji veže antigen kao tekuću formulaciju i u hermetički zatvorenoj posudi odabranoj iz skupine koju čine bočica, vrećica, prethodno napunjena štrcaljka, prethodno napunjeni autoinjektor, uložak za višekratnu štrcaljku, i aplikator.
Fillers are generally described above under “Fillers/Filler ingredients”. 
Punila su općenito opisana pod "Punila / Sastojci za punjenje"
(c9) an antigen-binding site comprising an L chain CDR1, 2, and 3 having at least 70% sequence identity with the amino acid sequences of SEQ ID NOs: 137, 138, and 139, respectively; and (c10) an antigen-binding site comprising an L chain CDR1, 2, and 3 having at least 70% sequence identity with the amino acid sequences of SEQ ID NOs: 177, 178, and 179, respectively; or 
(c9) mjesto vezanja antigena koje obuhvaća aminokiselinske sekvence L-lanca CDR-područja 1, 2 i 3 od SEQ ID NO: 137, 138 odnosno 139 (L-lanac CDR-područja od L408); i (c10) mjesto vezanja antigena koje obuhvaća aminokiselinske sekvence L-lanca CDR-područja 1, 2 i 3 od SEQ ID NO: 177, 178 odnosno 179 (L-lanac CDR-područja od L180); ili
LAL, TOC, Bio Burden and pH indicate whether the system is clean or not. 
LAL, TOC, biološko opterećenje i pH pokazuju da li je sustav čist ili nije.
A combination according to claim 1 or 2, wherein the B2 agonist is selected from the group comprising arformoterol, bambuterol, bitolterol, broxaterol, carbuterol, clenbuterol, dopexamine, fenoterol, hexoprenaline, ibuterol, isoprenaline, levosalbutamol, mabuterol, meluadrine, nolomirole, orciprenaline, pirbuterol, procaterol, (R,R)-formoterol, reproterol, ritodrine, rimoterol, salbutamol, sibenadet, sulfonterol, terbutaline and tulobuterol, optionally in the form of their racemates, their enantiomers, their diastereomers and mixtures thereof, and optionally their pharmacologically-compatible acid addition salts. 
Kombinacija u skladu s patentnim zahtjevom 3, naznačena time, da je inhibitor PDE4 odabran iz skupine koju čine cilomilast, roflumilast, denbufilin i tetomilast, po izboru u obliku njihovih racemata, enantiomera, dijastereomera i mješavina navedenog te, po izboru, njihovih farmakološki kompatibilnih adicijskih soli kiselina. Kombinacija u skladu s patentnim zahtjevom 4, naznačena time, da je inhibitor PDE4 roflumilast.
The solution of claim 6 wherein the fatty acid is oleic acid or lauric acid. 
Spoj prema patentnom zahtjevu 11, naznačen time što je masna kiselina oleinska kiselina ili laurinska kiselina.
The method of claim 1, wherein said supercritical carbon dioxide is firstly allowed to form a supercritical fluid in a supercritical trough at 69-345 bar (1000-5000 psi) and 30-100°C, and then said supercritical carbon dioxide carries said alcoholic liquid into a catalyst trough containing said esterification catalyst. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što navedeni superkritični ugljični dioksid najprije formira superkritični fluid u superkritičnom koritu pod tlakom od 6,9-34,5 MPa (1000-5000 psi) i na temperaturi od 30-100 °C, a zatim navedeni superkritični ugljični dioksid prenosi navedenu alkoholnu tekućinu u katalizatorsko korito, koje sadrži navedeni katalizator esterifikacije.
The computer system of claim 13, wherein the determining the ending address comprises computing the ending address as follows: 
Računalni sustav u skladu s patentnim zahtjevom 13., naznačen time što se određivanje krajnje adrese sastoji od izračunavanja krajnje adrese na sljedeći način: